Oncology Corporate Profile
MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|margetuximab||anti-HER2 monoclonal antibody||Breast cancer||III||Green Cross|
|margetuximab||anti-HER2 monoclonal antibody||Breast cancer||II||Green Cross|
|margetuximab (+pembrolizumab)||anti-HER2 monoclonal antibody||Gastric cancer||II||Green Cross|
|MGD006||dual-affinity re-targeting (DART) molecule||Acute Myelogenous Leukemia (AML)||I||Servier|
|MGD007||dual-affinity re-targeting (DART) molecule||Colorectal cancer||I||Servier|
|MGD011||bispecific dual-affinity re-targeting (DART) molecule||Lymphoma||I||Janssen|
|MGD006||dual-affinity re-targeting (DART) molecule||Myelodysplastic Syndrome (MDS)||I||Servier|
|enoblituzumab / MGA271||monoclonal antibody||Various cancer types||I|
|MGD009||dual-affinity re-targeting (DART) molecule||Various cancer types||I|
View additional information on product candidates here »
3/31/2017 11:03 am
[GlobeNewswire] - Rockville, MD, March 31, 2017--. MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment ...